PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32109511-10	2020	Montelukast significantly reduced JNK level and NFkappaB p65 expression, and inhibited proinflammatory cytokines (TNF-alpha and IL-6) as well as oxidative stress (MDA, NO, and GSH).	montelukast	0-11	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	57-60	
32303879-11	2021	Montelukast mitigated THIM-induced social deficit probably through alpha7nAChRs upregulation, NF-kappaB p65, Bax, and brain injury markers downregulation, thus suppressing THIM-induced neuronal toxicity and inflammation.	montelukast	0-11	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	104-107	
29268191-9	2018	Mechanistically, we found that montelukast suppressed LPS-induced nuclear translocation of NF-kappaB p65 as well as NF-kappaB transcriptional activity by inhibiting the phosphorylation and degradation of IkappaBalpha.	montelukast	31-42	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	101-104	
30862773-11	2019	Moreover, the upregulated pro-inflammatory factors production and p-p65 protein level in lung cells caused by hyperoxia were decreased by montelukast treatment.	montelukast	138-149	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	68-71	
24456746-5	2014	Blockade of CysLT1R by repeated treatment with montelukast (1 or 2 mg/kg, ig, 4 weeks) reduced Abeta1-42-induced CysLT1R expression and also suppressed Abeta1-42-induced increments of NF-kappaB p65, TNF-alpha, IL-1beta and caspase-3 activation, and Bcl-2 downregulation in the hippocampus and cortex.	montelukast	47-58	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	194-197